For research use only. Not for therapeutic Use.
TNIK-IN-5 is an efficient TNIK inhibitor with IC50 of 0.05 μM. TNIK-IN-5 efficiently inhibits Wnt signaling in intact cells. TNIK-IN-5 shows excellent in vitro anti-colorectal cancer activity[1].
TNIK-IN-5 (compound 8g) (1.25-5 μM; 48 hours) significantly inhibits the cell proliferation of HCT116 in a dose-dependent manner[1].
TNIK-IN-5 (1 μM; 24, 48 hours) strongly prevents HCT116 cells migration[1].
TNIK-IN-5 (10-40 μM; 48 hours) concentration-dependently inhibits the protein levels of β-catenin and TCF-4 in the nucleus, and significantly decreases the expression of Wnt target gene products, including Axin2 and c-Myc[1].
| Catalog Number | I043914 |
| CAS Number | 2754265-66-0 |
| Synonyms | 3-[(3-methoxyphenyl)methyl]-6-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1,3-benzoxazol-2-one |
| Molecular Formula | C22H17N3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H17N3O3/c1-27-18-4-2-3-14(9-18)13-25-19-6-5-15(11-20(19)28-22(25)26)17-10-16-7-8-23-21(16)24-12-17/h2-12H,13H2,1H3,(H,23,24) |
| InChIKey | DRHILHIKLGEWOH-UHFFFAOYSA-N |
| SMILES | COC1=CC=CC(=C1)CN2C3=C(C=C(C=C3)C4=CN=C5C(=C4)C=CN5)OC2=O |
| Reference | [1]. Luo X, Yang R, Li Y, Zhang L, Yang S, Li L. Discovery of benzo[d]oxazol-2(3H)-one derivatives as a new class of TNIK inhibitors for the treatment of colorectal cancer. Bioorg Med Chem Lett. 2022;67:128745. |
